Novo heralds promising PhIII diabetes data for once-weekly semaglutide

John Carroll

Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy . The Danish pharma company says that two doses of the drug–a key part of the pipeline–slashed HbA1c levels by 1.5% and 1.6%.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS